company background image
SCD

ZentivaBVB:SCD Stock Report

Last Price

RON2.40

Market Cap

RON1.7b

7D

-1.6%

1Y

-18.4%

Updated

26 Jan, 2022

Data

Company Financials
SCD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

SCD Stock Overview

Zentiva S.A. produces and markets preparations and medicines for human use in Romania and internationally.

Zentiva Competitors

Biofarm

BVB:BIO

RON782.4m

Antibiotice

BVB:ATB

RON392.1m

Johnson & Johnson

NYSE:JNJ

US$443.3b

Merck

NYSE:MRK

US$199.9b

Price History & Performance

Summary of all time highs, changes and price drops for Zentiva
Historical stock prices
Current Share PriceRON2.40
52 Week HighRON3.00
52 Week LowRON2.20
Beta0.41
1 Month Change-2.44%
3 Month Change-9.09%
1 Year Change-18.37%
3 Year Change-34.43%
5 Year Change21.83%
Change since IPO4,731.89%

Recent News & Updates

May 24
Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak Foundations

Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak Foundations

The recent earnings posted by Zentiva S.A. ( BVB:SCD ) were solid, but the stock didn't move as much as we expected. We...

Shareholder Returns

SCDRO PharmaceuticalsRO Market
7D-1.6%-3.6%-5.1%
1Y-18.4%9.9%22.7%

Return vs Industry: SCD underperformed the RO Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: SCD underperformed the RO Market which returned 22.7% over the past year.

Price Volatility

Is SCD's price volatile compared to industry and market?
SCD volatility
SCD Average Weekly Movement4.5%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.4%
10% most volatile stocks in RO Market6.8%
10% least volatile stocks in RO Market2.5%

Stable Share Price: SCD is not significantly more volatile than the rest of RO stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: SCD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1962782Simona Cocoshttps://www.zentiva.ro

Zentiva S.A. produces and markets preparations and medicines for human use in Romania and internationally. Its product portfolio includes tablets, capsules, and pellets, as well as injectable solutions. The company was formerly known as Sicomed S.A. and changed its name to Zentiva S.A. in January 2006.

Zentiva Fundamentals Summary

How do Zentiva's earnings and revenue compare to its market cap?
SCD fundamental statistics
Market CapRON1.67b
Earnings (TTM)RON60.57m
Revenue (TTM)RON642.62m

27.6x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SCD income statement (TTM)
RevenueRON642.62m
Cost of RevenueRON343.14m
Gross ProfitRON299.48m
ExpensesRON238.91m
EarningsRON60.57m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.087
Gross Margin46.60%
Net Profit Margin9.43%
Debt/Equity Ratio0%

How did SCD perform over the long term?

See historical performance and comparison

Valuation

Is Zentiva undervalued compared to its fair value and its price relative to the market?

27.62x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SCD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SCD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SCD is poor value based on its PE Ratio (27.6x) compared to the European Pharmaceuticals industry average (26.3x).

PE vs Market: SCD is poor value based on its PE Ratio (27.6x) compared to the RO market (12.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SCD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCD is good value based on its PB Ratio (2x) compared to the XE Pharmaceuticals industry average (2.9x).


Future Growth

How is Zentiva forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

9.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zentiva has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Zentiva performed over the past 5 years?

-7.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SCD has a high level of non-cash earnings.

Growing Profit Margin: SCD's current net profit margins (9.4%) are higher than last year (6.6%).


Past Earnings Growth Analysis

Earnings Trend: SCD's earnings have declined by 7.4% per year over the past 5 years.

Accelerating Growth: SCD's earnings growth over the past year (59.3%) exceeds its 5-year average (-7.4% per year).

Earnings vs Industry: SCD earnings growth over the past year (59.3%) exceeded the Pharmaceuticals industry 11.9%.


Return on Equity

High ROE: SCD's Return on Equity (7.3%) is considered low.


Financial Health

How is Zentiva's financial position?


Financial Position Analysis

Short Term Liabilities: SCD's short term assets (RON844.8M) exceed its short term liabilities (RON229.8M).

Long Term Liabilities: SCD's short term assets (RON844.8M) exceed its long term liabilities (RON21.8M).


Debt to Equity History and Analysis

Debt Level: SCD is debt free.

Reducing Debt: SCD had no debt 5 years ago.

Debt Coverage: SCD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SCD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Zentiva current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SCD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SCD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SCD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: SCD is not paying a notable dividend for the RO market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCD's dividend in 3 years as they are not forecast to pay a notable one for the RO market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average board tenure


CEO

Simona Cocos (54 yo)

12.25yrs

Tenure

Ms. Simona Cocos has been General Manager and Director of Zentiva S.A. since October 2009 and April 2010 respectively and has been its Chairman sine August 19, 2021. She graduated from the Faculty of Chemi...


Board Members

Experienced Board: SCD's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Zentiva S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Zentiva S.A.
  • Ticker: SCD
  • Exchange: BVB
  • Founded: 1962
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: RON1.673b
  • Shares outstanding: 697.02m
  • Website: https://www.zentiva.ro

Number of Employees


Location

  • Zentiva S.A.
  • 50 Theodor Pallady Boulevard
  • District 3
  • Bucharest
  • 32266
  • Romania

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/26 22:20
End of Day Share Price2022/01/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.